tirzepatide and belching Sulphur Burps from GLP-1 Injections (Mounjaro, Wegovy): How to Manage Them Is increased burping a normal

Description

[cited 2021 Mar 5]

Why this matters BIG TIME: Dual opportunity unlocked Covers Type-2 Diabetes and Chronic Weight Management two of Indias fastest-growing therapy segments Patent expiry catalyst India patent expiry expected in March 2026, setting the stage for large-scale generic entry Affordability revolution Generic semaglutide could be up to 70% cheaper, dramatically improving patient access Branded for impact Sematrinity Diabetes care Noveltreat Weight management Ready-to-use innovation Weekly dosing via prefilled pens (0.25 mg to 2.4 mg) convenience + adherence First-wave advantage Early DCGI approval gives Sun Pharma a strong launch edge in a fiercely competitive GLP-1 race Macro tailwinds Rising obesity, diabetes prevalence & metabolic disorders = long-term demand visibility Strategic takeaway: This isnt just another generic launch its a strategic bet on the future of metabolic healthcare in India

If you take Rybelsus as monotherapy (your only diabetes medication), your diabetes team may recommend: Increased home blood glucose monitoring checking levels at least four times daily (fasting and before meals) to identify any deterioration in control Dietary modifications maintaining a balanced, consistent carbohydrate intake whilst avoiding excessive simple sugars Specialist input in some cases, your diabetes team may recommend additional measures if your glucose control deteriorates significantly For patients on combination therapy , your existing medications (such as metformin) will typically be continued with possible dose adjustments